Lipocine To Start Testing Neuro-Steroid Candidate In Postpartum Depression Patients

by Vandana Singh, Benzinga Editor

June 14, 2021 9:37 AM | 1 min read |

The FDA has signed off Lipocine Inc's LPCN Investigational New Drug Application (IND) to initiate a Phase 2 study to evaluate LPCN 1154 for the treatment of postpartum depression (PPD) in adults.
A pharmacokinetic (PK) study to assess dose proportionality is planned to start in July 2021, with top-line results expected in the third quarter of 2021.
Following the PK study, a proof-of-concept study to evaluate the safety, tolerability, and efficacy of LPCN 1154 in adult female subjects is expected to start dosing in the fourth quarter of 2021.
Price Action: LPCN shares are up 12% at $1.49 during the market session on the last check Monday.

Posted In: Biotech News Penny Stocks Health Care FDA General Briefs Investigational New Drug Application Postpartum Depression

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.